In the current analysis from the METABRIC dataset, claudin-low breast cancers are shown to vary within their group, depending on the clinical phenotype (ER and/or HER2 positive versus ER negative/HER2 negative). This evidence concerns the gene ERBB2 and breast carcinoma.